Mobile Site ›

Circulating Tumor Cells and the CellSearch Assay


Receive notification when new Hot Topics are published:

CellSearch Use in MPC Clinical Trial8

Slide 21

April 2011

A multicenter, prospective clinical trial was conducted between 2004 and 2006 to determine whether the number of circulating tumor cells predicted disease progression and overall survival. The patient sample in this trial consisted of patients with hormone resistant, androgen-independent, or castration resistant tumors. A patient with a castration-resistant tumor is defined as a prostate cancer patient who has had 2 consecutive increases in prostate-specific antigen values despite hormone treatment.

The clinical trial enrolled 231 patients with metastatic prostate cancer who, despite treatment, had an increase in PSA level. Baseline circulating tumor cell counts were determined prior to initiation of a new line of therapy. Most patients (221 of 231) had 1 or more blood draws to monitor circulating tumor cell counts and PSA levels every 4 to 6 weeks after baseline. Progression-free survival was determined by identifying continued increases in PSA values, radiologic imaging evidence of disease progression, or other clinical signs. Overall survival was determined from baseline draw until time of death or until last contact with the patient.

CellSearch Use in MPC Clinical Trial8


Jump to section: